Sildenafil strength describes how much sildenafil is represented in a specific pharmaceutical product. Current U.S. products use several different expressions: milligrams per tablet or oral film, milligrams per milliliter for oral suspensions and both total milligrams per vial and milligrams per milliliter for injection.
The strength map depends strongly on product context. Erectile-dysfunction tablets commonly use 25 mg, 50 mg and 100 mg strengths; PAH-oriented sildenafil tablets use 20 mg; VYBRIQUE oral film is available in 25 mg, 50 mg, 75 mg and 100 mg; oral suspensions are labeled 10 mg/mL; and REVATIO injection contains 10 mg in 12.5 mL, equivalent to 0.8 mg/mL.
These numbers describe labeled pharmaceutical products, not interchangeable dosing units. Strength should be kept separate from dose, dosage regimen, indication and formulation.
Strength identifies the amount or concentration of sildenafil represented in a particular dosage form. A tablet or oral film is usually expressed as milligrams per unit, while a suspension or injection can be expressed as milligrams per milliliter.
Current sildenafil products are generally formulated with sildenafil citrate, while the labeled strength is expressed as the equivalent amount of sildenafil. The citrate salt therefore has a greater physical mass than the labeled sildenafil active-moiety amount.
Strength is a product-description concept. It does not establish how much should be administered, how often the product is used or whether two differently formulated products are clinically interchangeable.
| Term | Meaning | Sildenafil Example |
|---|---|---|
| Strength | Amount of sildenafil represented in one dosage unit | 50 mg per tablet |
| Concentration | Amount of sildenafil per defined liquid volume | 10 mg/mL |
| Total vial strength | Total sildenafil in an injectable container | 10 mg/12.5 mL |
| Active moiety | Sildenafil amount represented by the label | 20 mg sildenafil |
| Drug substance | Salt form used in many products | Sildenafil citrate |
| Dose | Amount actually administered in a treatment context | Separate from product strength |
Current U.S. sildenafil tablets fall into two prominent product contexts. ED-oriented products such as VIAGRA and corresponding generic sildenafil tablets are labeled in 25 mg, 50 mg and 100 mg strengths.
REVATIO and generic sildenafil tablets used in the pulmonary arterial hypertension product context are labeled at 20 mg per tablet.
The presence of a different tablet strength does not mean the active molecule is different. It reflects a different approved product, indication and labeling framework.
Detailed dosage-form information remains on the sildenafil tablets page.
| Tablet Context | Current Labeled Strengths |
|---|---|
| VIAGRA | 25 mg, 50 mg, 100 mg |
| Generic ED sildenafil tablets | 25 mg, 50 mg, 100 mg |
| REVATIO tablet | 20 mg |
| Generic PAH-context sildenafil tablet | 20 mg |
The most useful sildenafil tablet-strength map is 20 mg, 25 mg, 50 mg and 100 mg, but those numbers do not all belong to one interchangeable tablet family.
The 20 mg tablet is associated with the REVATIO and generic PAH product context. The 25 mg, 50 mg and 100 mg tablet strengths are associated with VIAGRA and generic ED products.
A strength comparison should therefore retain product identity rather than treating a lower milligram number as simply a smaller version of every other sildenafil tablet.
| Tablet Strength | Typical Current U.S. Product Context |
|---|---|
| 20 mg | REVATIO and generic PAH-oriented sildenafil tablets |
| 25 mg | VIAGRA and generic ED sildenafil tablets |
| 50 mg | VIAGRA and generic ED sildenafil tablets |
| 100 mg | VIAGRA and generic ED sildenafil tablets |
| 75 mg | Not a standard current VIAGRA tablet strength; appears in the VYBRIQUE oral-film product |
Current U.S. VIAGRA labeling lists three tablet strengths: 25 mg, 50 mg and 100 mg of sildenafil.
Each tablet contains sildenafil citrate equivalent to the labeled amount of sildenafil. The labeled number therefore refers to sildenafil rather than the total physical mass of sildenafil citrate in the tablet.
Current generic ED sildenafil tablets commonly mirror the same 25 mg, 50 mg and 100 mg strength set, although manufacturer appearance and inactive ingredients can differ.
The broader brand relationship is covered on the sildenafil and Viagra page.
| VIAGRA Feature | Current U.S. Label |
|---|---|
| Dosage form | Film-coated tablet |
| Lowest labeled tablet strength | 25 mg sildenafil |
| Intermediate labeled tablet strength | 50 mg sildenafil |
| Highest labeled tablet strength | 100 mg sildenafil |
| Drug substance | Sildenafil citrate |
| Strength expression | Equivalent amount of sildenafil |
Current REVATIO labeling uses different strength formats because the product family includes a tablet, powder for oral suspension and intravenous injection.
The tablet contains sildenafil citrate equivalent to 20 mg sildenafil. After reconstitution, the oral suspension contains 10 mg sildenafil per mL.
REVATIO injection contains 10 mg sildenafil in 12.5 mL of solution, which corresponds to 0.8 mg/mL.
These figures describe product composition. They should not be interpreted as mathematical instructions for converting between oral and intravenous treatment. The full product identity is covered on the sildenafil and Revatio page.
| REVATIO Dosage Form | Current Strength / Concentration |
|---|---|
| Tablet | 20 mg sildenafil |
| For oral suspension after reconstitution | 10 mg/mL sildenafil |
| Injection — total vial | 10 mg/12.5 mL |
| Injection — concentration | 0.8 mg/mL sildenafil |
Current U.S. sildenafil oral suspensions use a 10 mg/mL concentration, but the products are not all supplied in the same physical state.
REVATIO and several generic products are supplied as powder that becomes a 10 mg/mL suspension after labeled reconstitution. Current REVATIO labeling describes a final volume of 112 mL after reconstitution.
LIQREV is different because it is supplied as a ready-to-use oral suspension rather than as powder requiring reconstitution. It also contains 10 mg sildenafil per mL.
Matching concentration does not make the products identical in excipients, preparation, storage, labeling or population context. Those distinctions are covered on the sildenafil oral suspension page.
| Oral Suspension Product | Presentation | Sildenafil Concentration |
|---|---|---|
| REVATIO | Powder requiring reconstitution | 10 mg/mL after reconstitution |
| Generic sildenafil for oral suspension | Powder requiring reconstitution | 10 mg/mL after reconstitution |
| LIQREV | Ready-to-use oral suspension | 10 mg/mL |
| Concentration meaning | Amount of sildenafil in each milliliter | 10 mg sildenafil per 1 mL |
Current REVATIO injection is expressed both as a total quantity per vial and as a concentration. The single-dose vial contains 10 mg sildenafil in 12.5 mL.
Dividing the total sildenafil amount by the solution volume gives the labeled concentration of 0.8 mg/mL.
Current product description further states that each milliliter contains 1.124 mg sildenafil citrate, equivalent to 0.8 mg sildenafil. This is another example of why citrate mass and labeled sildenafil strength are different quantities.
Injection-specific formulation and route information remains on the sildenafil injection page.
| Injection Feature | Current REVATIO Value |
|---|---|
| Total sildenafil per vial | 10 mg |
| Total solution volume | 12.5 mL |
| Sildenafil concentration | 0.8 mg/mL |
| Sildenafil citrate per mL | 1.124 mg |
| Equivalent sildenafil per mL | 0.8 mg |
| Route | Intravenous |
Strength describes what is physically contained in a pharmaceutical dosage unit. Dose describes the amount administered in a particular use context, and dosage regimen adds timing and frequency.
For example, a product being labeled as a 20 mg tablet establishes tablet composition; it does not by itself state how many tablets are administered or how frequently. Likewise, a 10 mg/mL suspension concentration does not independently define the volume used in an individual regimen.
Keeping these concepts separate is especially important for sildenafil because ED, PAH, oral and intravenous products have different labeling frameworks.
Regimen information belongs on the sildenafil dosage page.
| Term | Definition | Example |
|---|---|---|
| Strength | Drug amount in one dosage unit | 50 mg per tablet |
| Concentration | Drug amount per liquid volume | 10 mg/mL |
| Dose | Amount administered at one time | Requires regimen context |
| Dosage regimen | Amount plus timing and frequency | Not determined by strength alone |
Formulation identifies the physical dosage form, while strength describes how much sildenafil that dosage form represents.
The same numerical strength can appear in different formulations. For example, 25 mg, 50 mg and 100 mg exist as both VIAGRA-type tablet strengths and VYBRIQUE oral-film strengths, but the two dosage forms are not the same pharmaceutical product.
Conversely, a formulation can have a strength not found in another formulation. VYBRIQUE includes a 75 mg oral film, while 75 mg is not a current VIAGRA tablet strength.
The complete dosage-form map remains on the sildenafil formulations page.
| Formulation | Current Sildenafil Strength Example |
|---|---|
| ED tablet | 25 mg, 50 mg, 100 mg |
| PAH tablet | 20 mg |
| Oral film | 25 mg, 50 mg, 75 mg, 100 mg |
| Oral suspension | 10 mg/mL |
| Injection | 10 mg/12.5 mL (0.8 mg/mL) |
Generic sildenafil should not be treated as one universal tablet product. Current U.S. generic products reflect different reference-product and indication contexts.
Generic ED-oriented sildenafil tablets are available in 25 mg, 50 mg and 100 mg strengths. Separate generic PAH-oriented sildenafil tablets are available at 20 mg.
Generic sildenafil for oral suspension is also available as powder that is reconstituted to 10 mg/mL. Product appearance, excipients, manufacturer and packaging can differ even when the labeled sildenafil strength matches another approved product.
The relationship between generic products and their branded reference contexts is covered on the generic sildenafil page.
| Generic Product Context | Current Strength Pattern |
|---|---|
| Generic ED sildenafil tablet | 25 mg, 50 mg, 100 mg |
| Generic PAH sildenafil tablet | 20 mg |
| Generic sildenafil for oral suspension | 10 mg/mL after reconstitution |
| Manufacturer | Can vary while the labeled strength remains equivalent |
| Inactive ingredients / appearance | Can differ between manufacturers |
Matching strength means that two products represent the same nominal amount of sildenafil per dosage unit. It does not, by itself, establish bioequivalence.
Regulatory bioequivalence evaluates systemic exposure using pharmacokinetic measures such as AUC and Cmax under a defined comparison framework.
This distinction is particularly important when products use different dosage forms. A tablet and an oral suspension can both represent sildenafil at comparable administered amounts while requiring separate evidence to establish pharmacokinetic equivalence.
The statistical and regulatory framework remains on the sildenafil bioequivalence page.
| Concept | What It Establishes |
|---|---|
| Same nominal strength | Same labeled amount of sildenafil per unit |
| Same active ingredient | Both products contain sildenafil |
| Same formulation | Same general physical dosage-form type |
| Bioequivalence | Regulatory comparison of systemic exposure |
| AUC | Integrated exposure metric used in bioequivalence analysis |
| Cmax | Peak-exposure metric used in bioequivalence analysis |
A milligram number should always be attached to a product and dosage form. Sildenafil's current U.S. product map makes this especially clear because several indication and formulation frameworks coexist.
Twenty milligrams commonly identifies a PAH tablet product; 25 mg, 50 mg and 100 mg identify ED tablet strengths; 75 mg appears in the current oral-film family; 10 mg/mL describes oral suspension; and 0.8 mg/mL describes the REVATIO injectable concentration.
The numerical value alone therefore cannot identify indication, formulation or route. Product name, dosage form and labeling context are needed to interpret what the strength actually represents.
| Strength / Concentration | Current Product Context |
|---|---|
| 20 mg | REVATIO and generic PAH tablets |
| 25 mg | VIAGRA/generic ED tablet and VYBRIQUE oral film |
| 50 mg | VIAGRA/generic ED tablet and VYBRIQUE oral film |
| 75 mg | VYBRIQUE oral film |
| 100 mg | VIAGRA/generic ED tablet and VYBRIQUE oral film |
| 10 mg/mL | REVATIO/generic reconstituted oral suspension and LIQREV ready-to-use suspension |
| 10 mg/12.5 mL | REVATIO injection total vial strength |
| 0.8 mg/mL | REVATIO injection concentration |
A strength reference answers what products contain, not which strength or formulation is appropriate in an individual situation.
The fact that several strengths exist does not create a simple progression in which one product is automatically substituted for another. Indication, formulation, route, labeling and clinical context remain relevant.
This distinction is particularly important for 20 mg PAH tablets, 25/50/100 mg ED tablets, 75 mg oral film and injectable sildenafil, which should not be reduced to a single interchangeable milligram ladder.
General label-based regimen information remains on the sildenafil dosage page.
| Topic | Covered Here? |
|---|---|
| Current labeled product strengths | Yes |
| Liquid concentrations | Yes |
| Active-moiety vs citrate strength expression | Yes |
| Product and formulation context | Yes |
| Individual strength selection | No |
| Personalized dosing | No |
| Route conversion | No |
Current U.S. ED-oriented sildenafil tablets, including VIAGRA and generic equivalents, are available in 25 mg, 50 mg and 100 mg strengths. REVATIO and generic PAH-oriented sildenafil tablets use a 20 mg strength.
Yes. Current VYBRIQUE sildenafil oral film is available in 25 mg, 50 mg, 75 mg and 100 mg strengths. The 75 mg strength is an oral-film product and is not a current VIAGRA tablet strength.
Current REVATIO and generic powder-for-suspension products contain 10 mg/mL sildenafil after reconstitution. LIQREV is a separate ready-to-use sildenafil suspension that also contains 10 mg/mL.
Current REVATIO injection contains 10 mg sildenafil in 12.5 mL of solution, corresponding to a concentration of 0.8 mg/mL.
No. In current U.S. labeling, 20 mg tablets are associated with the REVATIO and generic PAH product context, while 25 mg is one of the ED tablet strengths and is also available as a VYBRIQUE oral-film strength.
Sildenafil citrate is the salt form used in many products, while labeled strengths are expressed as the equivalent amount of sildenafil active moiety. The citrate salt therefore has a greater physical mass than the sildenafil amount printed as the product strength.
No. Strength describes the pharmaceutical product. Dose and dosage regimen describe how much is administered and on what schedule, and those concepts belong to the product's prescribing context rather than the strength number alone.